- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 07.07. | Galera Therapeutics, Inc. - 8-K, Current Report | 11 | SEC Filings | ||
| 15.05. | Galera Therapeutics, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| GALERA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 14.05. | Galera Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 19.04. | Obsidian, Galera Therapeutics Merger Comes With $350M Infusion for Cancer Drug Trials | 3 | MedCity News | ||
| 15.04. | Obsidian, Galera Therapeutics to advance cell therapy following reverse merger | 4 | BioPharma Dive | ||
| 15.04. | Obsidian Therapeutics To Merge With Galera Therapeutics In Reverse Merger | - | RTTNews | ||
| 15.04. | Obsidian Therapeutics to go public via Galera Therapeutics merger | 2 | Investing.com | ||
| 15.04. | Fusion mit Galera Therapeutics: Obsidian Therapeutics strebt Börsengang an | 3 | Investing.com Deutsch | ||
| 15.04. | RTW Biotech Opp. - Obsidian Therapeutics reverse merger with Galera Therapeutics | - | RNS | ||
| 14.04. | Galera Therapeutics und Obsidian kündigen Fusion und 350-Millionen-Dollar-Finanzierung an | 2 | Investing.com Deutsch | ||
| 14.04. | Galera Therapeutics to merge with Obsidian in $350M deal | 2 | Investing.com | ||
| 14.04. | Cell therapy biotech Obsidian leverages Galera Therapeutics reverse merger to go public | 1 | FierceBiotech | ||
| 14.04. | Fusion von Galera Therapeutics und Obsidian Therapeutics: Neues Biotech-Unternehmen sichert sich 350 Millionen US-Dollar | 1 | Investing.com Deutsch | ||
| 14.04. | Obsidian Therapeutics, Inc. and Galera Therapeutics, Inc. Announce Merger Agreement and $350 Million Concurrent Private Placement | 205 | Business Wire | • Combined company to operate as Obsidian Therapeutics, Inc. and to advance Obsidian's pipeline of novel engineered TIL cell therapies for the treatment of patients with solid tumors.
• Obsidian's... ► Artikel lesen | |
| 14.04. | Galera Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 03.04. | Galera Therapeutics bündelt jährliche Hauptversammlungen für 2025 und 2026 und setzt Termin für Mai fest | 4 | Investing.com Deutsch | ||
| 03.04. | Galera Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 19.03. | Galera Therapeutics, Inc. - 10-K, Annual Report | 2 | SEC Filings | ||
| 12.02. | Galera Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 22.10.25 | Galera Therapeutics Announces Acquisition of Dismutase Mimetics Portfolio by Toronto-based Biossil for up to $105 Million | 1.054 | GlobeNewswire (Europe) | Galera has entered into an Asset Purchase Agreement with Toronto-based Biossil for Galera's dismutase mimetics portfolio, including all avasopasem and rucosopasem formulations and indications. The... ► Artikel lesen |
20 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CRISPR THERAPEUTICS | 41,765 | -1,66 % | 3 Reasons to Buy CRISPR Therapeutics Stock | ||
| NOVOCURE | 13,385 | -6,72 % | JPMorgan nimmt NovoCure-Bewertung mit "Neutral" wieder auf | ||
| SPERO THERAPEUTICS | 1,395 | +1,97 % | Spero Announces Royalty Financing Deal With Affiliates Of Healthcare Royalty | LONDON (dpa-AFX) - Spero Therapeutics (SPRO) announced a $105 million non-recourse non-dilutive royalty financing transaction with affiliates of Healthcare Royalty, or HCRx, a royalty acquisition... ► Artikel lesen | |
| PRECISION BIOSCIENCES | 7,440 | +2,34 % | Precision BioSciences, Inc.: Precision BioSciences Announces Late-Breaking Poster Presentation for PBGENE-HBV at European Association for the Study of the Liver Congress 2026 | Late-breaking poster presentation to highlight new biopsy data demonstrating elimination and inactivation of cccDNA from the ongoing Phase 1 ELIMINATE-B trial in chronic hepatitis B
Precision... ► Artikel lesen | |
| BOLT BIOTHERAPEUTICS | 4,290 | 0,00 % | Bolt Biotherapeutics, Inc.: Bolt Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Business Update | First-in-class immune-stimulating antibody conjugate BDC-4182 Phase 1/2 study ongoing, initial clinical data expected in 3Q 2026 Cash balance of $23.9 million as of March 31, 2026 anticipated to fund... ► Artikel lesen | |
| QIAGEN | 35,965 | -0,55 % | Qiagen: Die Gerüchte gehen in die zweite Runde | Im Januar wurde gemunkelt, Qiagen könnte unmittelbar vor einer Übernahme stehen. Doch am Ende verlief die Sache im Sand. Die Aktie, die damals einen Riesensatz nach oben gemacht hatte, fiel tiefer als... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 133,99 | -0,07 % | Laufende Fusionskontrollverfahren: AbbVie Inc., North Chicago/Illinois/USA; Erwerb von Anteilen an und alleiniger Kontrolle über die Apogee Therapeutics, Inc., San Francisco/CA/USA | Datum der Anmeldung:07.07.2026Aktenzeichen:B3-76/26Unternehmen:AbbVie Inc., North Chicago/Illinois/USA; Erwerb von Anteilen an und alleiniger Kontrolle über die Apogee Therapeutics, Inc., San Francisco/CA/USAProduktmärkte:Biotechnologie... ► Artikel lesen | |
| ERASCA | 19,160 | +0,74 % | Erasca, Inc.: Erasca Announces Updated Preliminary Phase 1 Data and Registration-Enabling Plans for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors | At RDE of 32 mg QD, encouraging monotherapy responses with 57% uORR in 2L+ KRAS G12X pancreatic cancer in U.S. trial and median relative dose intensity of 100% Monotherapy has been generally well-tolerated... ► Artikel lesen | |
| TREVI THERAPEUTICS | 19,075 | +9,82 % | Trevi Therapeutics, Inc.: Trevi Therapeutics Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Updates | Following the End-of-Phase 2 meeting with the FDA, the Company gained alignment on its Phase 3 program for the treatment of patients with idiopathic pulmonary fibrosis-related chronic cough On track... ► Artikel lesen | |
| VERA THERAPEUTICS | 38,500 | -1,61 % | Weekly Buzz: Johnson & Johnson, Vera Therapeutics Get FDA Nod; Vertex Pharmaceuticals Snaps Up Crinetics Pharmaceuticals; Satellos Bioscience Aces DMD Trial; Ionis Pharmaceuticals Misses Key Goal | NEW BRUNSWICK (dpa-AFX) - This week featured a steady stream of regulatory milestones, strategic dealmaking, and pivotal clinical trial updates, alongside missed trial goals across the biotech... ► Artikel lesen | |
| COGENT BIOSCIENCES | 39,060 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) | Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 314,42 | +2,02 % | Piper Sandler reiterates Praxis Precision Medicines stock rating | ||
| KYMERA THERAPEUTICS | 115,77 | 0,00 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Appoints Elizabeth Laws, Ph.D., as Senior Vice President, Global Program Team Leader for KT-621, First-in-Class, Oral STAT6 Degrader | Dr. Laws, former immunology leader at Sanofi, will oversee global development of Kymera's KT-621 program KT-621 parallel Phase 2b trials advancing in AD and asthma, with data expected by year-end... ► Artikel lesen | |
| BEAM THERAPEUTICS | 27,530 | 0,00 % | Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development | Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up... ► Artikel lesen | |
| TANGO THERAPEUTICS | 28,490 | +3,08 % | Mizuho hebt Kursziel für Tango Therapeutics nach vielversprechenden Studiendaten an |
GALERA THERAPEUTICS INC gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GALERA THERAPEUTICS INC finden Sie auf Wallstreet Online.